The drug binds CD16A on NK cells (and NKp46) to activate them while simultaneously binding CD123 on tumor cells, bridging NK cells to CD123+ targets and inducing NK-mediated lysis (perforin/granzyme) of the CD123-expressing tumor cells; CD16A+ NK cells are not the cells killed.